当前位置: X-MOL 学术Adv. Funct. Mater. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Multifunctional Supramolecular Filament Hydrogel Boosts Anti-Inflammatory Efficacy In Vitro and In Vivo
Advanced Functional Materials ( IF 18.5 ) Pub Date : 2022-01-05 , DOI: 10.1002/adfm.202109173
Jie Deng 1 , Deqing Lin 2 , Xiangyu Ding 2 , Yuan Wang 2 , YuHan Hu 2 , Hui Shi 2 , Lin Chen 2 , Bingyang Chu 3 , Lei Lei 2 , Chunmei Wen 1 , Jiaqing Wang 2 , Zhiyong Qian 3 , Xingyi Li 2
Affiliation  

Peptide-drug conjugates (PDCs) are an important class of therapeutic agents that combine one or more active molecules with a short peptide via a biodegradable spacer to generate prodrugs. Here an antioxidant (i.e., 3,5-dihydroxybenzoic acid), a non-steroidal anti-inflammatory drug (i.e., ibuprofen, IPF), and a self-assembled peptide motif (i.e., Gly-Phe-Phe-Tyr-Asp, GFFYD) are integrated to produce a peptide-drug amphiphile, which self-assembles to form hydrogel and further exerts the synergistic effects, and consequently emerges high therapeutic efficacy. In the in vitro study toward lipopolysaccharide-activated RAW264.7 macrophages, the resulting hydrogel significantly reduces the production of cytokines (e.g., IL-1β, IL-6 and tumor necrosis factor-α (i.e., TNF-α)) compared with that of native IPF via the inhibition of nuclear factor-κB (i.e., NF-κB), janus kinase-signal transducer and activator of transcription (i.e., JAK-STAT) signals and NLR family pyrin domain containing 3 (i.e., NLRP3) inflammasome activation. Moreover, a rabbit model of endotoxin induced uveitis evidences the superior therapeutic efficacy of the resulting hydrogel over that of clinically used 0.1 wt% diclofenac sodium eyedrop. Overall, this work offers new insights into the anti-inflammatory mechanism of PDCs hydrogel and presents the therapeutic values in the treatment of ocular disorders, and ultimately fulfils the potential clinical benefits of PDCs.

中文翻译:

多功能超分子长丝水凝胶在体外和体内提高抗炎功效

肽-药物偶联物 (PDC) 是一类重要的治疗剂,它通过可生物降解的间隔物将一个或多个活性分子与短肽结合以产生前药。这里是抗氧化剂(即 3,5-二羟基苯甲酸)、非甾体抗炎药(即布洛芬、IPF)和自组装肽基序(即 Gly-Phe-Phe-Tyr-Asp、 GFFYD) 被整合产生一种肽-药物两亲物,其自组装形成水凝胶并进一步发挥协同作用,从而出现高治疗效果。在针对脂多糖激活的 RAW264.7 巨噬细胞的体外研究中,与水凝胶相比,所得水凝胶显着降低了细胞因子(例如,IL-1β、IL-6 和肿瘤坏死因子-α(即 TNF-α))的产生。通过抑制核因子-κB(即,NF-κB)、janus 激酶信号转导和转录激活因子 (即 JAK-STAT) 信号和含有 3 个 (即 NLRP3) 炎性体激活的 NLR 家族 pyrin 结构域。此外,内毒素诱导的葡萄膜炎的兔模型证明了所得水凝胶的治疗效果优于临床使用的 0.1 wt% 双氯芬酸钠滴眼液。总体而言,这项工作为 PDCs 水凝胶的抗炎机制提供了新的见解,并展示了在眼部疾病治疗中的治疗价值,并最终实现了 PDCs 的潜在临床益处。内毒素诱导的葡萄膜炎的兔模型证明,所得水凝胶的治疗效果优于临床使用的 0.1 wt% 双氯芬酸钠滴眼液。总体而言,这项工作为 PDCs 水凝胶的抗炎机制提供了新的见解,并展示了在眼部疾病治疗中的治疗价值,并最终实现了 PDCs 的潜在临床益处。内毒素诱导的葡萄膜炎的兔模型证明,所得水凝胶的治疗效果优于临床使用的 0.1 wt% 双氯芬酸钠滴眼液。总体而言,这项工作为 PDCs 水凝胶的抗炎机制提供了新的见解,并展示了在眼部疾病治疗中的治疗价值,并最终实现了 PDCs 的潜在临床益处。
更新日期:2022-01-05
down
wechat
bug